Skip to main
CVS
CVS logo

CVS Health (CVS) Stock Forecast & Price Target

CVS Health (CVS) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 65%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

CVS Health's strong financial outlook is underscored by an increase in the adjusted EPS estimate for 2026 to $7.19, reflecting a robust growth rate of 17.3% from the revised 2025 EPS. The company's strategic partnerships, particularly with Novo, are expected to enhance the affordability and accessibility of GLP-1 medications, further attracting plan sponsors due to preferred formulary positions. Additionally, there is anticipated improvement in the medical loss ratio (MLR), projected to drop 100 basis points year-over-year to 90.3%, indicating effective cost management and favorable medical cost trends.

Bears say

CVS Health faces significant challenges that hinder its ability to achieve material earnings per share (EPS) growth, particularly due to headwinds in Medicare Advantage utilization. Current projections indicate that FY26 EPS could fall approximately 10% below estimates, compounded by the assumption of a valuation decline to 7.5x, a level consistent with historical troughs. Additionally, the company is exposed to a range of risks, including elevated cost trends, regulatory pressures related to Medicare funding, and competitive threats to its retail pharmacy business that further exacerbate its negative outlook.

CVS Health (CVS) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 65% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVS Health (CVS) Forecast

Analysts have given CVS Health (CVS) a Buy based on their latest research and market trends.

According to 17 analysts, CVS Health (CVS) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVS Health (CVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.